


# CSACI 2021

ANNUAL SCIENTIFIC  
M E E T I N G

OCTOBER



28-30

## FINAL PROGRAM

(As of October 27, 2011)  
ALL TIMES EASTERN

## THURSDAY, OCTOBER 28, 2021 – ALL TIMES EASTERN

- 1215-1515** FIT (Fellows-In-Training) WORKSHOP  
MODERATORS: DRS. ANGELIKI BARLAS, ZAINAB ABDURRAHMAN AND MERIEM LATROUS AND AUDREY SEGAL
- 1215-1225** INTRODUCTION
- 1225-1310** SESSION 1: TRANSITION TO PRACTICE – LIVE PANEL DISCUSSION  
MODERATORS: DR. ANGELIKI BARLAS, DR. AUDREY SEGAL, DR. ZAINAB ABDURRAHMAN AND DR. MERIEM LATROUS  
SPEAKERS: DR. STEPHANIE ERDLER, DR. LANA ROSENFELD, DR. LORI CONNORS, DR. ALEXANDRA LANGLOIS, DR. DEREK CHU  
OBJECTIVES: BY THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:  
1. IDENTIFY COMMON ISSUES WHEN TRANSITIONING TO PRACTICE  
2. DISCUSS THE DIFFERENCES BETWEEN ACADEMIC AND COMMUNITY PRACTICES
- 1310-1315** BREAK
- 1315-1400** SESSION 2: ORAL IMMUNOTHERAPY – LIVE PANEL DISCUSSION  
MODERATORS: DR. ANGELIKI BARLAS, DR. AUDREY SEGAL, DR. ZAINAB ABDURRAHMAN AND DR. MERIEM LATROUS  
SPEAKERS: DR. VICTORIA COOK, DR. MARY MCHENRY, DR. MARIAM HANNA, DR. EDMOND CHAN  
OBJECTIVES: BY THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:  
1. COMPARE AND CONTRAST VARIOUS APPROACHES TO OFFERING ORAL IMMUNOTHERAPY IN AN ALLERGY PRACTICE  
2. IDENTIFY COMMON BARRIERS TO OFFERING ORAL IMMUNOTHERAPY
- 1400-1405** BREAK
- 1405-1425** ELECTIONS
- 1425-1430** BREAK
- 1430-1515** SESSION 3: CONTACT DERMATITIS AND PATCH TESTING  
MODERATOR: DR. ANGELIKI BARLAS  
1430-1500 SPEAKER: DR. SANDY SKOTNICKI, TORONTO, ON, ASSISTANT PROFESSOR, UNIVERSITY OF TORONTO DERMATOLOGIST, AUTHOR, RANDOM HOUSE  
OBJECTIVES: BY THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:  
1. DEVELOP A DIAGNOSTIC APPROACH TO CONTACT DERMATITIS  
2. UNDERSTAND THE KEY ALLERGENS IN CONTACT DERMATITIS AND THE USE OF PATCH TESTING FOR THIS DIAGNOSIS  
3. DISCUSS PRACTICAL RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF CONTACT DERMATITIS FOR THE PRACTISING ALLERGIST
- 1500-1515** DISCUSSION PERIOD

## THURSDAY, OCTOBER 28, 2021

**1630-1640**            **OPENING BY DR. VANDER LEEK, PRESIDENT OF THE CSACI AND DR. HAROLD KIM, 2021 CSACI PROGRAM CHAIR AND PAST PRESIDENT**

**1640-1800**            **PLENARY SESSION I – PHYSICIAN WELLNESS AND AWARENESS  
MODERATORS: DRs. ELISSA ABRAMS & DAVID FISCHER**

**1640-1710**        **SPEAKER: DR. MAMTA GAUTAM, OTTAWA, ON**

**TOPIC: PHYSICIAN WELLNESS COVID AND BEYOND**

**OBJECTIVES:**

**AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:**

- 1. EVALUATE THE IMPACT OF COVID-19 ON PHYSICIAN PERSONAL HEALTH AND RESILIENCE (CanMEDs Leader role)**
- 2. IDENTIFY STRATEGIES TO IMPROVE PHYSICIAN WELLNESS DURING COVID-19 (CanMEDs Leader role)**

**1715-1745**        **SPEAKER: DR. KELEIGH JAMES, OTTAWA, ON**

**TOPIC: UNPERCEIVED NEEDS IN ALLERGY/IMMUNOLOGY: PERSPECTIVES FROM THE CMPA**

**OBJECTIVES:**

**AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:**

- 1. ANALYZE THE ROLE OF THE CMPA IN THE ALLERGIST/IMMUNOLOGIST'S PRACTICE**
- 2. PROPOSE STRATEGIES FOR INVOLVEMENT OF THE CMPA IN THE ALLERGIST/IMMUNOLOGIST'S PRACTICE**

**1745-1800**        **DISCUSSION PERIOD**

## THURSDAY, OCTOBER 28, 2021

1900-1945

PLENARY SESSION II – TRANSITION FOR SEVERE ASTHMA

MODERATORS: DRS. ELISSA ABRAMS & DAVID FISCHER

*This session was co-developed with GlaxoSmithKline and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

1900-1930      SPEAKER: DR. PATRICK MITCHELL, DUBLIN, IRELAND

TOPIC: PEDIATRIC INTO ADULT ASTHMA: HOW DO WE TRANSITION

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. RECOGNIZE PROBLEMS AND FORMULATE STRATEGIES FOR THE MANAGEMENT OF ASTHMA IN TEENAGERS.
2. IDENTIFY DIFFERENCES IN NATIONAL/INTERNATIONAL GUIDELINES FOR ASTHMA CARE BETWEEN ADULT AND PEDIATRIC PATIENTS
3. CREATE STRATEGIES THAT HELP PATIENTS 'BRIDGE THE GAP' FROM PEDIATRIC TO ADULT CARE IN ASTHMA (CanMEDs Advocacy Role)

1930-1945      DISCUSSION PERIOD

2000-2100

FIT/NREP SOCIAL

2000-2100

ZOOM ROOMS

## FRIDAY, OCTOBER 29, 2021

0900-1025 POSTER VIEWING AND EXHIBIT HALL

1025-1030 WELCOME AND INTRODUCTIONS – DR. HAROLD KIM

1030-1130 PLENARY SESSION III – DRUG AND VACCINE ALLERGIES  
MODERATORS: DRs. MOSHE BEN SHOSHAN AND ANNE ELLIS

1030-1050 SPEAKER: DR. GINA LACUESTA, HALIFAX, NS

TOPIC: COVID-19 VACCINE FOR THE ALLERGIST & IMMUNOLOGIST: WHERE ARE WE NOW?

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DESCRIBE POTENTIAL ALLERGENS AND DIAGNOSTIC WORK-UP OF COVID-19 VACCINE ALLERGY
2. DISCUSS MANAGEMENT APPROACH OF COVID-19 VACCINE ALLERGY
3. DESCRIBE MANAGEMENT APPROACHES TO COVID-19 ADVERSE EVENTS

---

*This session was co-developed with Miravo Healthcare and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

1055-1115 SPEAKER: DR. KIM BLUMENTHAL, BOSTON, MA

TOPIC: COMPLEX DRUG ALLERGY: AN APPROACH TO OUR MOST DIFFICULT PATIENTS  
OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DESCRIBE THE KEY CLINICAL CONSIDERATIONS IN PATIENTS WITH COMPLEX DRUG ALLERGY
2. PLAN DIAGNOSTIC AND MANAGEMENT STRATEGIES FOR PATIENTS WITH COMPLEX DRUG ALLERGY

1115-1130 DISCUSSION PERIOD

1130-1200 POSTER VIEWING, EXHIBIT HALL AND NUTRITION BREAK

## FRIDAY, OCTOBER 29, 2021

1200-1230

PLENARY SESSION IV – PRIMARY IMMUNODEFICIENCY

*This session was co-developed with Takeda and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

MODERATORS: DRS. MOSHE BEN SHOSHAN AND ANNE ELLIS

1200-1220    SPEAKER: DR. CHARLOTTE CUNNINGHAM RUNDLES,  
NEW YORK, NY

TOPIC: MONITORING IN PRIMARY IMMUNODEFICIENCY: THE WHO, WHAT, WHERE  
AND WHY

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. EXPLAIN KNOWLEDGE GAPS RELATED TO MONITORING PATIENTS WITH PRIMARY IMMUNODEFICIENCY (CanMEDs Collaborator Role)
2. DESCRIBE STRATEGIES TO BALANCE RISK AND BENEFIT WHEN MONITORING PATIENTS WITH PRIMARY IMMUNODEFICIENCY

1220-1230    DISCUSSION PERIOD

1240-1315

CSACI AWARDS PRESENTATIONS

## FRIDAY, OCTOBER 29, 2021

**1325-1405**      **KEYNOTE PRESENTATIONS - TOPIC: HISTORY OF ALLERGY IN CANADA: CELEBRATING THE 75<sup>TH</sup> ANNIVERSARY OF THE CSACI**

**MODERATORS: DR. TIM VANDER LEEK AND DR. HAROLD KIM**

**1325-1340**      **SPEAKER: DR. BILL MOOTE, LONDON, ON**

**1342-1357**      **SPEAKER: DR. SUSAN WASERMAN, HAMILTON, ON**

**OBJECTIVES:**

**AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:**

- 1. DESCRIBE THE “WHO, WHAT, WHERE, WHEN, WHY AND HOW” ABOUT THE FORMATION OF THE CSACI**
- 2. DISCUSS AT LEAST ONE MAJOR CONTRIBUTION THAT A CSACI MEMBER HAS MADE TO THE FIELD OF ALLERGY AND IMMUNOLOGY DURING THEIR CAREER**
- 3. DISCUSS THE FUTURE OF CSACI**

**1357-1405**      **DISCUSSION PERIOD**

**1405-1425**      **POSTER VIEWING, EXHIBIT HALL AND NUTRITION BREAK**

FRIDAY, OCTOBER 29, 2021

**1425-1555**      **THREE CONCURRENT SESSIONS (A, B, C)**

**1425-1555**      **(A) PLENARY SESSION V – WORKSHOPS**

**MODERATORS: DRS. LORI CONNORS AND VICTORIA COOK**

1425-1555	TWO CONCURRENT WORKSHOPS
1425-1505	SESSION # 1
1505 – 1515 TRANSITION	FACILITATORS: DRS. DAVID FISCHER, TIM OLYNYCH, GHISLAINE ISABWE, JULIA UPTON, VICKI COOK, RAYMOND MAK AND YASMIN MOOLANI-MERCHANT
1515 - 1555	TITLE: DRUG ALLERGY - CHALLENGING CASES <b>(MEMBERS TO SUBMIT CASES BEFOREHAND)</b> OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO: 1. MANAGE CHALLENGING DRUG ALLERGY CASES 2. COLLABORATE WITH COLLEAGUES IN CHALLENGING CASE MANAGEMENT
1425-1505	SESSION # 2
1505-1515 TRANSITION	FACILITATORS: DRS. WADE WATSON, KYLA HILDEBRAND, STEPHEN BETSCHEL, JACKIE QUIRT, LANA ROSENFELD, CHRISTINE SONG, SCOTT CAMERON AND LORI CONNORS
1515-1555	TITLE: THE THINGS YOU DO NOT KNOW THAT YOU NEED TO KNOW OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO: 1. DISCUSS UNPERCEIVED NEEDS IN THE CONTEXT OF OUR SPECIALTY 2. CREATE A LEARNING PLAN TO ADDRESS UNPERCEIVED NEEDS



FRIDAY, OCTOBER 29, 2021

1425-1555

**(B) PLENARY SESSION VI - BASIC SCIENCE AND IMMUNOLOGY**

**MODERATORS: DRS. BEATA DERFALVI AND HARISSIOS VLIAGOFTIS**

1425-1555	BASIC SCIENCE AND IMMUNOLOGY
1425-1430	INTRODUCTION BY DRS. DERFALVI AND VLIAGOFTIS
1430-1450	<p>SESSION #1 SPEAKER: DR. IVONA AKSENTIJEVICH, BETHESDA, MD TITLE: IMMUNOBIOLOGY AND GENETICS OF AUTOINFLAMMATORY DISEASES – NEW PATHWAYS, GENES AND INHERITANCE PATTERNS OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"><li>1. EXPLAIN THE STRATEGIES AND METHODS THAT LEAD TO THE DISCOVERY OF NEW GENETIC AUTOINFLAMMATORY DISEASES</li><li>2. CATEGORIZE SYSTEMIC AUTOINFLAMMATORY DISEASES BASED ON MAJOR INFLAMMATORY PATHWAYS</li><li>3. DESCRIBE NEW INHERITANCE PATTERNS IN THE GENETICS OF SYSTEMIC AUTOINFLAMMATORY DISEASES</li></ol>
1452-1512	<p>SESSION # 2 SPEAKER: DR. MARINKA TWILT, CALGARY, AB TITLE: HOW TO APPROACH AUTOINFLAMMATORY DISEASES IN CLINIC? OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"><li>1. IDENTIFY THE MAIN CLINICAL PRESENTATIONS AND PATTERN OF SYMPTOMS IN PERIODIC FEVERS/SYSTEMIC AUTOINFLAMMATORY DISEASES</li><li>2. EXPLAIN WHEN TO SEND GENETIC TESTING FOR AUTOINFLAMMATORY DISEASES</li><li>3. FORMULATE AN APPROACH TO THE DIAGNOSIS, TREATMENT AND CARE OF UNDIFFERENTIATED SYSTEMIC AUTOINFLAMMATORY DISEASES</li></ol>

FRIDAY, OCTOBER 29, 2021

1425-1555

**(B) PLENARY SESSION VI - BASIC SCIENCE AND IMMUNOLOGY - continued**

**MODERATORS: DRS. BEATA DERFALVI AND HARISSIS VLIAGOFTIS**

1425-1555	BASIC SCIENCE AND IMMUNOLOGY
1512-1520	BREAK
1520-1540	<p>SESSION # 3 SPEAKER: DR. HELENE DECALUWE, MONTREAL, QUEBEC TITLE: HYPERINFLAMMATION AND TARGETED IMMUNOTHERAPIES IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"><li>1. DESCRIBE THE ROLE OF INNATE AND ADAPTIVE IMMUNE CELLS AND MAJOR CYTOKINES IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)-RELATED HYPERINFLAMMATION</li><li>2. IDENTIFY THE GENETIC DEFECTS ASSOCIATED WITH HLH</li><li>3. SUMMARIZE TARGETED IMMUNOTHERAPY IN HLH</li></ol>
1540-1555	DISCUSSION PERIOD

## FRIDAY, OCTOBER 29, 2021

**1425-1555**

### (C) PLENARY SESSION VII – ALLIED HEALTH WORKSHOP

MODERATOR: DR. JENNIFER PROTUDJER

1425-1555	ALLIED HEALTH WORKSHOP
1425-1430	INTRODUCTION BY DR. PROTUDJER
1430-1500	<p><b>SESSION # 1</b>  <i>This session was co-developed with Nutricia and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.</i></p> <p><b>SPEAKERS:</b> DR. MARION GROETCH, NEW YORK, NY and DR. CARINA VENTER, DENVER, CO</p> <p><b>TITLE:</b> PROPOSED FOOD ALLERGY EDUCATOR PROGRAM AND CURRICULUM</p> <p><b>OBJECTIVES:</b>            AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"> <li>1. EXPLAIN HOW A FOOD ALLERGY EDUCATION PROGRAM COULD BENEFIT CANADIAN HEALTHCARE PROFESSIONALS.</li> <li>2. ARTICULATE THE KEY CONTENT AREAS OF THE AMERICAN-BASED FOOD ALLERGY EDUCATION PROGRAM FOR HEALTHCARE PROFESSIONALS.</li> <li>3. DESCRIBE THE BENEFITS OF, AS WELL AS LESSONS LEARNED IN THE US PROGRAM.</li> </ol>
1500-1510	BREAK
1510-1540	<p><b>SESSION # 2</b>  <b>SPEAKERS:</b> MS. ROSEMARY INVIK, VICTORIA, BC, MS. HÉLÈNE LEROUX, MONTREAL, QUEBEC AND MR. BROCK WILLIAMS, VANCOUVER, BC</p> <p><b>TITLE:</b> ORAL IMMUNOTHERAPY (OIT) ALLIED HEALTH</p> <p><b>OBJECTIVES:</b>            AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"> <li>1. SUMMARIZE THE ROLE OF ALLIED HEALTH PROFESSIONALS IN THE IMPLEMENTATION OF ORAL IMMUNOTHERAPY PROGRAMS.</li> <li>2. OUTLINE STRATEGIES TO HELP FAMILIES NAVIGATE BARRIERS TO CARE IN ORAL IMMUNOTHERAPY.</li> <li>3. RECOMMEND PATIENT-CENTERED STEPS TO ADDRESS COMMON PROBLEMS DURING ORAL IMMUNOTHERAPY BUILDUP AND MAINTENANCE THERAPY.</li> </ol>
1540-1555	DISCUSSION PERIOD

1600-1615

POSTER VIEWING, EXHIBIT HALL AND NUTRITION BREAK

## FRIDAY, OCTOBER 29, 2021

1615-1715

FIT BOWL

MODERATOR: DR. ANNE ELLIS

OBJECTIVES: By the end of this session participants will be able to:

1. Delineate interesting facts in allergy and immunology

1730-1830

ZOOM ROOM - VIRTUAL WINE TASTING EVENT - YOU MUST REGISTER TO PARTICIPATE TO THIS EVENT

## SATURDAY, OCTOBER 30, 2021

0900-0930

YOGA SESSION

0945-1015

POSTER VIEWING AND EXHIBIT HALL

**1015-1130**

**TWO CONCURRENT SESSIONS (A, B)**

**(A) PLENARY SESSION VIII – FOOD AND AEROALLERGEN IMMUNOTHERAPY**

MODERATORS: DRS. PHILIPPE BÉGIN AND EDMOND CHAN

1015-1130	<b>TWO CONCURRENT SESSIONS: FOOD AND AEROALLERGEN IMMUNOTHERAPY</b>
1015-1045	<p><b>SESSION # 1</b> PANELISTS: DRS. MARY MCHENRY, HALIFAX, NS, DOUG MACK, BURLINGTON, ON, VICTORIA COOK, VICTORIA, BC TITLE: GETTING STARTED WITH ORAL IMMUNOTHERAPY (OIT) – PART TWO: PANEL DISCUSSION OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"><li>1. IDENTIFY PRACTICAL CHALLENGES WITH IMPLEMENTATION OF OIT IN THEIR PRACTICES</li><li>2. SELECT APPROPRIATE STRATEGIES TO OVERCOME PRACTICAL CHALLENGES</li><li>3. DISCUSS ASPECTS OF OIT THAT CAN AND/OR SHOULD BE PERSONALIZED TO THE INDIVIDUAL PATIENT</li></ol>
1045-1055	DISCUSSION PERIOD

SATURDAY, OCTOBER 30, 2021

1015-1130

**(A) PLENARY SESSION IX – FOOD AND AEROALLERGEN IMMUNOTHERAPY**

MODERATORS: DRS. PHILIPPE BÉGIN AND EDMOND CHAN

1055-1120	<p><b>SESSION # 2</b></p> <p><i>This session was co-developed with Stallergenes Greer and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.</i></p> <p>PANELISTS: DRS. ANNE ELLIS, KINGSTON, ON JACLYN QUIRT, HAMILTON, ON, HAROLD KIM, KITCHENER, ON</p> <p>TITLE: IMMUNOTHERAPY PERSONALIZED MEDICINE: PANEL DISCUSSION</p> <p>OBJECTIVES:</p> <p>AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:</p> <ol style="list-style-type: none"><li>1. DEVELOP AN APPROACH TO PRESCRIBING PERSONALIZED ALLERGEN IMMUNOTHERAPY.</li><li>2. DISCUSS SOLUTIONS FOR DEALING WITH COMPLICATIONS WITH IMMUNOTHERAPY.</li></ol>
1120-1130	DISCUSSION PERIOD

SATURDAY, OCTOBER 30, 2021

1015-1130

**(B) PLENARY SESSION X – WORKSHOP ON IMMUNOGENETICS**

MODERATORS: DRS. BEATA DERFALVI AND VY KIM

1015-1130	WORKSHOP ON IMMUNOGENETICS AND DIAGNOSTIC STRATEGIES IN INBORN ERRORS OF IMMUNITY
1015-1040	SESSION # 1 SPEAKER: DR. ROSHINI ABRAHAM, COLUMBUS, OH TITLE: DIAGNOSTIC POTPOURRI: FLOW CYTOMETRY AND GENOMICS FOR THE DIAGNOSIS OF INBORN ERRORS OF IMMUNITY OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO: 1. COMPARE AND CONTRAST THE DIFFERENT METHODS OF GENETIC TESTING USED FOR THE DIAGNOSIS OF INBORN ERRORS OF IMMUNITY (IEI) 2. DESCRIBE HOW FLOW CYTOMETRY-BASED FUNCTIONAL TESTS CAN CONFIRM GENETIC DIAGNOSES OF IEI
1040-1045	TRANSITION
1045-1110	SESSION # 2 SPEAKER: DR. SERGIO ROSENZWEIG, BETHESDA, MD TITLE: STRATEGIES, PRACTICAL TIPS AND FUNCTIONAL TESTS FOR THE INTERPRETATION OF VARIANT OF UNKNOWN SIGNIFICANCE IN GENETIC TESTING FOR IEI OBJECTIVES: AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO: 1. DESCRIBE THE INTERPRETATION OF A VARIANT OF UNKNOWN SIGNIFICANCE 2. IDENTIFY IMMUNOLOGICAL FUNCTIONAL TESTS AVAILABLE THAT CAN HELP TO CONFIRM GENETIC DIAGNOSES 3. FORMULATE AN APPROACH TO VALIDATING VARIANTS OF UNKNOWN SIGNIFICANCE IN GENETIC TESTING FOR INBORN ERRORS OF IMMUNITY
1110-1130	DISCUSSION PERIOD

## SATURDAY, OCTOBER 30, 2021

1130-1200 POSTER VIEWING, EXHIBIT HALL AND NUTRITION BREAK

1200-1230 PLENARY SESSION XI – BIOLOGICS IN ALLERGY  
MODERATORS: DRS. ANDY O’KEEFE AND CHRISTINE SONG

*This session was co-developed with Sanofi and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

1200-1220 SPEAKER: DR. JONATHAN CORREN, LOS ANGELES, CA

TOPIC: BIOLOGICS FOR ALLERGISTS: WHAT DRIVES THE SELECTION

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. EXPLAIN COMMON PATHOPHYSIOLOGY FOR CONDITIONS DRIVEN BY INFLAMMATION.
2. DISCUSS BIOLOGIC SELECTION IN PATIENTS WITH COMMON COMORBIDITIES SEEN IN OUR PATIENT POPULATION
3. DESCRIBE POTENTIAL BARRIERS TO ACCESS TO BIOLOGICS (CanMEDs Advocacy Role)

1220-1230 DISCUSSION PERIOD

1230-1245 NUTRITION & NETWORKING BREAKS

1245-1310 PLENARY SESSION XII – SKIN DISEASE AND ALLERGY  
MODERATORS: DRS. ANDY O’KEEFE AND CHRISTINE SONG

*This session was co-developed with Pfizer Canada ULC and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

1245-1305 SPEAKER: DR. MELINDA GOODERHAM, PETERBOROUGH, ON

TOPIC: CURRENT AND FUTURE THERAPIES IN ATOPIC DERMATITIS

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. RECOGNIZE KEY INFLAMMATORY MEDIATORS OF ATOPIC DERMATITIS
2. OPERATIONALIZE THIS UNDERSTANDING IN THE CONTEXT OF NOVEL THERAPIES FOR ATOPIC DERMATITIS.

1305-1310 DISCUSSION PERIOD

## SATURDAY, OCTOBER 30, 2021

1312-1340

PLENARY SESSION XIII – DRUG SAFETY AND ALLERGY  
MODERATORS: DRS. ANDY O’KEEFE AND CHRISTINE SONG

*This session was co-developed with Medexus and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

1312-1332     SPEAKER: DR. ANA MARIA GIMÉNEZ-ARNAU, BARCELONA, SPAIN  
TOPIC: URTICARIA/ANGIOEDEMA SAFETY ISSUES OF ANTIHISTAMINES  
OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DISCUSS SAFETY UPTITRATION OF ANTIHISTAMINES
2. DESCRIBE POTENTIAL ADVERSE EVENTS WITH ANTIHISTAMINES AND MONITORING FOR ADVERSE EVENTS

1332-1340     DISCUSSION PERIOD

1345-1455

ORAL ABSTRACT QUICK SNAPPERS (THREE TO FOUR CONCURRENT ROOMS)  
MODERATORS: DRS. CATHERINE BIGGS, SAMIRA JEIMY AND CHRISTINE MCCUSKER  
OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DISCUSS NOVEL RESEARCH IN CLINICAL IMMUNOLOGY AND ALLERGY

1455-1515

NUTRITION & NETWORKING BREAKS

1515-1620

PLENARY SESSION XIV - LITERATURE REVIEW  
MODERATORS: DRS. KYLA HILDEBRAND AND WADE WATSON  
OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. REVIEW THE RESULTS OF IMPORTANT PUBLICATIONS IN THE PAST YEAR
2. CRITIQUE THE NEWEST INFORMATION WITH RESPECT TO PREVIOUS KNOWLEDGE
3. DISCUSS THE IMPLICATIONS OF NEW FINDINGS IN YOUR PRACTICE OR THAT COULD BENEFIT FROM FURTHER REVIEW

1515-1530     SPEAKER: DR. SANDY KAPUR, HALIFAX, NS  
TOPIC: KEY PAPERS IN PEDIATRIC ALLERGY FROM 2020 AND 2021

1532-1547     DR. DAVID FISCHER, BARRIE, ON  
TOPIC: KEY PAPERS IN ADULT ALLERGY FROM 2020 AND 2021

1549-1604     SPEAKER: DR. CHRISTINE MCCUSKER, MONTREAL, QC  
TOPIC: KEY PAPERS IN IMMUNOLOGY FROM 2020 AND 2021

1604-1620     DISCUSSION PERIOD



## SATURDAY, OCTOBER 30, 2021

1620-1630 EXHIBIT HALL AND NUTRITION BREAK

1630 -1715 PLENARY SESSION XV – PRO/CON DEBATE:  
MODERATORS: DRS. KYLA HILDEBRAND AND WADE WATSON

*This session was co-developed with Pfizer Canada ULC and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

TOPIC: THERE IS NO NEED FOR AN EMERGENCY ROOM VISIT AFTER APPROPRIATE HOME TREATMENT OF ANAPHYLAXIS

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DISCUSS THE EVIDENCE WHICH SUPPORTS/REFUTES THE RECOMMENDATION ABOUT AN EMERGENCY DEPARTMENT VISIT AFTER TREATMENT OF AN ALLERGIC REACTION WITH EPINEPHRINE IN THE COMMUNITY
2. DISCUSS THE IMPLICATIONS FOR PATIENTS WITH ANY CHANGES IN RECOMMENDATIONS IN MANAGEMENT OF ANAPHYLAXIS IN THE COMMUNITY SETTING

1630-1640 PRO: DR. THOMAS B. CASALE, PALMETTO, FLORIDA

1642-1652 CON: DR. JOANNE YEUNG, VANCOUVER, BC

1654-1659 PRO: REBUTTAL – DR. TIM VANDER LEEK, EDMONTON, AB

1700-1705 CON: REBUTTAL – DR. TIM VANDER LEEK

1705-1715 DISCUSSION PERIOD

1720-1750 PLENARY SESSION XVI – MAST CELL DISEASE  
MODERATORS: DRS. KYLA HILDEBRAND AND WADE WATSON

1720-1740 SPEAKER: DR. CEM AKIN, ANN ARBOR, MI

TOPIC: APPROACH TO MAST CELL DISEASE (MCAS) WITH NEGATIVE TESTS

OBJECTIVES:

AT THE END OF THIS SESSION, PARTICIPANTS WILL BE ABLE TO:

1. DESCRIBE THE DIAGNOSTIC CRITERIA FOR MCAS
2. DEVELOP AN APPROACH TO MANAGEMENT FOR PATIENTS WHO SUSPECT THEY HAVE MCAS, WHEN INVESTIGATIONS ARE NEGATIVE
3. COMMUNICATE EFFECTIVELY WITH PATIENTS WHO SUSPECT THEY HAVE MCAS, WHEN INVESTIGATIONS ARE NEGATIVE (CanMEDs Communicator role)

1740-1750 DISCUSSION PERIOD

1750-1800 CLOSING REMARKS BY THE CSACI PRESIDENT - DR. TIM VANDER LEEK

## PRE-RECORDED SESSIONS

TOPIC: REVIEW OF COVID EXPERIENCE IN NORTH AMERICA

SPEAKERS: DRS. ELISSA ABRAMS, WINNIPEG, MB AND MATT GREENHAWT, DENVER, CO

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:

OBJECTIVES:

1. REVIEW COVID-19 VACCINATION ALLERGIC REACTIONS
  2. REVIEW VACCINE ANAPHYLAXIS HISTORICALLY IN NORTH AMERICA
  3. REVIEW CURRENT ALLERGY GUIDELINES REGARDING APPROACH TO A REACTION TO THE COVID-19 VACCINE
- 

TOPIC: ANAPHYLAXIS IN 2021: WHAT HAVE WE LEARNED AND NEED TO LEARN?

SPEAKER: DR. PAUL TURNER, LONDON, ENGLAND

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:

OBJECTIVES:

1. REVIEW RECENT STUDIES ON PATHOPHYSIOLOGY OF ANAPHYLAXIS
  2. DISCUSS IMPACT OF EPINEPHRINE ON ANAPHYLAXIS IN RECENT TRIALS
  3. PROPOSE FUTURE APPROACH TO MANAGING ANAPHYLAXIS
- 

CO-DEVELOPED TOPIC: ETHNODERMATOLOGY UPDATE FOR THE ALLERGIST/IMMUNOLOGIST WITH A FOCUS ON THE CANADIAN CONTEXT

*This session was co-developed with Leo Pharma and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

SPEAKER: DR. RACHEL ASINIWASIS, REGINA, SASKATCHEWAN

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:

OBJECTIVES:

1. EXPLAIN GENERAL APPROACH TO ETHNODERMATOLOGY
  2. DESCRIBE SPECIFIC ISSUES IN FIRST NATIONS PATIENTS
  3. DISCUSS MANAGEMENT OF SEVERE ATOPIC DERMATITIS IN DIFFERENT ETHNIC GROUPS
- 

TOPIC: ORAL FOOD CHALLENGES: IS THERE ANY SCIENCE?

SPEAKER: DR. ANNA NOWAK-WEGRZYN, NEW YORK, NY

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:

OBJECTIVES:

1. DESCRIBE GENERAL PURPOSE OF ORAL FOOD CHALLENGES IN ALLERGY
2. PROVIDE BRIEF OVERVIEW OF THE CLINICAL DATA AND GUIDELINES APPROACH FOR ORAL FOOD CHALLENGES
3. GIVE AN OPTIMAL APPROACH TO ORAL FOOD CHALLENGES IN IGE-MEDIATED FOOD ALLERGY AND FOOD PROTEIN-INDUCED ENTEROCOLITIS SYNDROME (FPIES)

## PRE-RECORDED SESSIONS

### CO-DEVELOPED TOPIC: HEREDITARY ANGIOEDEMA (HAE) UPDATE

*This session was co-developed with CSL Behring and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

MODERATOR: DR. STEPHEN BETSCHEL, TORONTO, ON - PANELISTS: DR. ALLEN KAPLAN, CHARLESTON, NC, DR. HUGO CHAPDELAINE, MONTREAL, QC AND DR. DAWN GOODYEAR, CALGARY, AB

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:  
OBJECTIVES:

1. DISCUSS CURRENT APPROACH TO DIAGNOSIS OF HAE
  2. DISCUSS CURRENT APPROACH TO MANAGEMENT OF HAE
- 

### CO-DEVELOPED TOPIC: BIOLOGICS AND PREGNANCY

*This session was co-developed with Novartis and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology.*

SPEAKER: DR. JENNIFER NAMAZY, SAN DIEGO, CA

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:  
OBJECTIVES:

- DISCUSS THE IMPACT OF ASTHMA DURING PREGNANCY
  - DELINEATE THE TREATMENT OF SEVERE ASTHMA DURING PREGNANCY
  - EXPLAIN HOW BIOLOGICS TRANSFER THROUGH THE PLACENTA
  - INTERPRET THE CURRENTLY AVAILABLE SAFETY DATA ON ASTHMA BIOLOGICS DURING PREGNANCY
- 

SPEAKER: JACKIE GRUBER, WINNIPEG, MG

### TOPIC: CONSIDERATIONS IN HEALTH SCIENCES AND HEALTH EQUITY

AT THE END OF THESE SESSIONS, PARTICIPANTS WILL BE ABLE TO:  
OBJECTIVES:

- DESCRIBE GENDER AND ETHNOCULTURAL DISPARITIES IN HEALTH SCIENCES IN CANADA
- ARTICULATE HOW SUCH DISPARITIES CONTRIBUTE TO SUSTAINED INEQUITY
- EXPLAIN STRATEGIES THAT MAY ENHANCE EQUITY ACROSS AND WITHIN HEALTH SCIENCES IN CANADA